A5106227984- Reproductive tract infections research
- Reproductive System and Pregnancy
- Probiotics and Fermented Foods
- Transgenic Plants and Applications
- Gut microbiota and health
- Pelvic floor disorders treatments
- HIV Research and Treatment
- Adolescent Sexual and Reproductive Health
- Syphilis Diagnosis and Treatment
- Urinary Tract Infections Management
- Herpesvirus Infections and Treatments
- Helicobacter pylori-related gastroenterology studies
- Reproductive Health and Contraception
- Cancer Research and Treatments
- T-cell and B-cell Immunology
- Mycobacterium research and diagnosis
- Seaweed-derived Bioactive Compounds
- Reproductive Physiology in Livestock
- Renal cell carcinoma treatment
- HIV/AIDS oral health manifestations
- Preterm Birth and Chorioamnionitis
- Pancreatic and Hepatic Oncology Research
- Cancer Cells and Metastasis
- Monoclonal and Polyclonal Antibodies Research
Osel (United States)
2014-2025
University of California, San Francisco
2020
University of California, San Diego
2020
Emmes (United States)
2020
Ruth M. Rothstein CORE Center
2020
Rush University Medical Center
2020
Washington University in St. Louis
2020
Woosuk University
2015
University of Shizuoka
2015
King Saud University
2015
Bacterial vaginosis affects 15 to 50% of women reproductive age, and recurrence is common after treatment with an antibiotic agent. The high incidence suggests the need for new treatments prevent recurrent bacterial vaginosis.
Women are at significant risk of human immunodeficiency virus (HIV) infection, with the cervicovaginal mucosa serving as a major portal for entry. Female-initiated preventatives, including topical microbicides, urgently needed to help curtail HIV/AIDS pandemic. Here we report on development novel, live microbicide that employs natural vaginal strain Lactobacillus jensenii engineered deliver potent HIV inhibitor cyanovirin-N (CV-N). To facilitate efficient expression CV-N by this bacterium,...
is often associated with vaginal dysbiosis and bacterial vaginosis (BV), which are risk factors for adverse gynecological obstetric outcomes. To discover natural inhibitors of
Eradication of human immunodeficiency virus type 1 (HIV-1) by vaccination with epitopes that produce broadly neutralizing antibodies is the ultimate goal for HIV prevention. However, generating appropriate immune responses has proven difficult. Expression vaginal colonizing lactobacilli provides an approach to passively target these mucosa. We tested feasibility expressing single-chain and single-domain (dAbs) in Lactobacillus be used as a topical microbicide/live biotherapeutic....
The vaginal microbiota is a determinant for the risk of preterm birth (PTB). Dominance niche by Lactobacillus crispatus associates with term delivery. This first observational clinical study live biotherapeutics ( CTV-05 (LACTIN-V)) in pregnant women at high-risk PTB. primary aim was to explore safety, tolerability and acceptability LACTIN-V pregnancy. Women were offered course 14 weeks gestation five consecutive days followed weekly administration six weeks. Participants up 15, 18-, 20-,...
Abstract A Lactobacillus-dominated vaginal microbiota (VMB) has been associated with health and considered an important host defense mechanism against urogenital infections. Conversely, depletion of lactobacilli increased microbial diversity, amplifies the risk adverse gynecologic obstetric outcomes. common clinical condition that exemplifies dysbiosis is bacterial vaginosis (BV). BV currently treated antibiotics, but frequently recurs, due in part to persistent failure repopulate vagina....
MucoCept is a biotherapeutic for prevention of HIV-1 infection in women and contains human, vaginal Lactobacillus jensenii that has been genetically enhanced to express the entry inhibitor, modified cyanovirin-N (mCV-N). The objective this study was develop solid dosage form supports sustained colonization at levels previously shown, with freshly prepared cultures, protect macaques from SHIV test formulation macaque model. Vaginally disintegrating tablets were by lyophilizing formulated...
Introduction Recent studies in vitro fertilisation (IVF) patients have associated abnormal vaginal microbiota (AVM) with poor clinical pregnancy rates of 6%–9% per embryo transfer. The biological plausibility for this finding is hypothesised to be ascending infection the endometrium which turn hampers implantation. New molecular based diagnosis may offer advantages compared microscopical AVM has huge inter-study variability ranging from 4 38%; however, important question whether screening...
Abstract Background We have previously demonstrated that the orally administered, live bacterial product CBM588 can augment clinical outcomes with cabo/nivo in pts mRCC (Ebrahimi et al ASCO 2023). As it is postulated this effect may be mediated through changes systemic immunity, we sought to characterize serum cytokine profile induced by CBM588. Methods Pts untreated clear cell, papillary or sarcomatoid histology were enrolled. Key eligibility criteria included Karnofsky performance status ≥...
(Abstracted from N Engl J Med 2020;382:1906–1915) Worldwide, 15% to 50% of women reproductive age have bacterial vaginosis (BV) and are treated with an antibiotic agent. Within 3 months after treatment, the infection recurs in 20% 75% women.
Results The optimized CV-N expression cassette was stably integrated in single copy into the lactobacillus bacterial chromosome, and resolved from extraneous plasmid DNA antibiotic resistance determinants. L. jenseniiexpressed dramatically decreased CCR5-trophic HIVBaL infectivity vitro, with an IC50 of 0.3 nM. Histological examination CD1 mice, which were intra-vaginally inoculated jensenii expressing CV-N, revealed that associated keratinized epithelium present during estrus or free...
Results The CV-N-producing L. jensenii retained important characteristics of the native bacterial phenotype and secreted high levels full-length CV-N that completely inhibited infectivity CCR5-tropic HIVBaL in vitro, with an IC50 near 1 nM. We further demonstrated this strain was capable association epithelial cells vaginal lumen CD-1 mice, expressed vivo model when cultured cervicovaginal lavage fluid pigtailed macaques. are evaluating potential regulatory issues, formulations,...
Results A human vaginal isolate of Lactobacillus jensenii was engineered, by stable integration an optimized expression cassette into the bacterial genome, to secrete high levels highly potent HIV inhibitor, CV-N. The L. jenseniiexpressed CV-N dramatically decreases infectivity CCR5-tropic HIVBaL and CXCR4-tropic HIVIIIB in vitro. We further demonstrate that this strain is genetically can transiently colonize animal mucosa, while retaining important characteristics native phenotype.
Women worldwide continue to be infected with HIV at an alarming rate.The majority of Human Immunodeficiency Virus (HIV) infections occur by the mucosal route during unprotected vaginal sexual intercourse.Several commensal Lactobacillus species generally dominate microbiota healthy women childbearing age and are associated health a reduced risk bacterial vaginosis (BV), human immunodeficiency virus (HIV), other sexually transmitted (STIs), including herpes simplex virus-2 (HSV-2), Neisseria...
Abstract Background The vaginal microbiota is a determinant for the risk of preterm birth (PTB). Dominance niche by Lactobacillus crispatus associates with term delivery. Vaginal administration as live biotherapeutic in non-pregnant women leads to colonisation and reduced recurrence bacterial vaginosis urinary tract infections. This first in-pregnancy observational clinical study biotherapeutics ( CTV-05 (LACTIN-V, Osel)) cohort pregnant at high-risk PTB. primary aim was explore safety,...
SUMMARY A tuberculous lesion was found in the prepuce of a 5-year-old tuberculin-positive herd bull at necropsy. Microscopic examination revealed granulomas with Langhans’-type giant cells; Mycobacterium bovis isolated. The had been used artificial insemination procedures and for natural breeding.